Drug intelligence / Profile preview

MAXIHEME-PLUS

Development stage: Unknown
Lead developer: Ingram Biosciences
Modality: Small Molecules
Administration: Oral

Overview

MAXIHEME-PLUS is a nutraceutical supplement developed by Ingram Biosciences. It contains heme iron polypeptide, a form of iron derived from hemoglobin. Unlike traditional non-heme iron salts (such as ferrous sulfate), heme iron polypeptide is absorbed through a distinct pathway in the small intestine, which typically results in higher bioavailability and a lower incidence of gastrointestinal side effects like constipation and nausea. It is primarily used for the prevention and treatment of iron deficiency and iron deficiency anemia.

Brand names: MAXIHEME-PLUS
Other names: Heme Iron Polypeptide

Targets

SLC46A1 (Proton-coupled folate transporter)

Beyond the preview

Go deeper on MAXIHEME-PLUS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAXIHEME-PLUS.

Explore the full profile